Copy to clipboard 
Cigna Healthcare, a health benefits provider for 19 million Americans, established national coverage for Relievant Medsystems’ Intracept Procedure. The coverage expands access to the procedure, when clinically appropriate, to patients in all 50 states as well as Washington D.C. and Puerto Rico.
The decision from Cigna Healthcare comes shortly after Palmetto GBA, a Medicare Administrative Contractor (MAC) covering Medicare patients in Alabama, Georgia, North Carolina, South Carolina, Tennessee, Virginia, and West Virginia, published a final Local Coverage Determination (LCD) for basivertebral nerve (BVN) ablation that expanded access to more than 5 million covered lives in March of 2023.
More than 10,000 patients have now been treated with Relievant Medsystems’ minimally invasive Intracept Procedure, reported to be the only FDA-cleared treatment for chronic vertebrogenic low back pain. The same-day outpatient procedure uses targeted radiofrequency energy to stop the basivertebral nerve from transmitting pain signals to the brain and takes approximately one hour to perform.
Based on existing data, patients typically experience minimal post-procedure discomfort and a quick recovery. The Intracept Procedure is supported by strong scientific evidence, including two Level I randomized clinical trials and data showing improvements are sustained more than five years post-procedure.
“This positive coverage determination from Cigna Healthcare, one of the country’s leading health benefit providers, is vastly impactful in increasing patient and physician access to our proven treatment for vertebrogenic pain,” said Tyler Binney, President and CEO of Relievant Medsystems. “We look forward to further educating payers on the clinical benefits of the Intracept Procedure in providing significant and durable pain relief, as well as reducing overall healthcare utilization.”
Source: Relievant Medsystems
Cigna Healthcare, a health benefits provider for 19 million Americans, established national coverage for Relievant Medsystems' Intracept Procedure. The coverage expands access to the procedure, when clinically appropriate, to patients in all 50 states as well as Washington D.C. and Puerto Rico.
The decision from Cigna Healthcare comes shortly...
Cigna Healthcare, a health benefits provider for 19 million Americans, established national coverage for Relievant Medsystems’ Intracept Procedure. The coverage expands access to the procedure, when clinically appropriate, to patients in all 50 states as well as Washington D.C. and Puerto Rico.
The decision from Cigna Healthcare comes shortly after Palmetto GBA, a Medicare Administrative Contractor (MAC) covering Medicare patients in Alabama, Georgia, North Carolina, South Carolina, Tennessee, Virginia, and West Virginia, published a final Local Coverage Determination (LCD) for basivertebral nerve (BVN) ablation that expanded access to more than 5 million covered lives in March of 2023.
More than 10,000 patients have now been treated with Relievant Medsystems’ minimally invasive Intracept Procedure, reported to be the only FDA-cleared treatment for chronic vertebrogenic low back pain. The same-day outpatient procedure uses targeted radiofrequency energy to stop the basivertebral nerve from transmitting pain signals to the brain and takes approximately one hour to perform.
Based on existing data, patients typically experience minimal post-procedure discomfort and a quick recovery. The Intracept Procedure is supported by strong scientific evidence, including two Level I randomized clinical trials and data showing improvements are sustained more than five years post-procedure.
“This positive coverage determination from Cigna Healthcare, one of the country’s leading health benefit providers, is vastly impactful in increasing patient and physician access to our proven treatment for vertebrogenic pain,” said Tyler Binney, President and CEO of Relievant Medsystems. “We look forward to further educating payers on the clinical benefits of the Intracept Procedure in providing significant and durable pain relief, as well as reducing overall healthcare utilization.”
Source: Relievant Medsystems
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
